Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 8, 1999, Pages 683-692

  Gross, Myron ^a   Kruisselbrink, Teresa ^b   Anderson, Kristin ^a   Lang, Nicholas ^c,d   McGovern, Paul ^a   Delongchamp, Robert ^e   Kadlubar, Fred ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^e NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RESEARCH; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

AGED; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETICS, POPULATION; HUMANS; MALE; MODELS, GENETIC; PANCREATIC NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC; UNITED STATES;

EID: 0033382567     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Raunio, H., Husgafvel-Pursiainen, K., Anttila, S., Hietanen, E., Hirvonen, A., and Pelkonen, O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility: a review. Gene, 159: 113-121, 1995.
2. Kadlubar, F. F., Butler, M. A., Kaderlik, K. R., Chou, H-C., and Lang, N. P. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ. Health Perspect., 98: 69-74, 1992.
3. Ayesh, R., and Smith, R. L. Genetic polymorphism in human toxicology. In: P. Turner and G. N. Volans (eds.), Recent Advances in Clinical Pharmacology and Toxicology, pp. 137-157. Edinburgh: Churchill Livingstone, 1989.
4. Hein, D. W. Acetylator genotype and arylamine-induced carcinogenesis. Biochim. Biophys. Acta, 948: 37-66, 1988.
5. Weber, W. W. The acetylator genes and drug response. New York: Oxford University Press, 1987.
6. Grant, D. M., Blum, M., Beer, M., and Myer, U. A. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol., 39: 184-191, 1991.
7. Grant, D. M., Josephy, P. D., Lord, H. L., and Morrison, L. D. Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines. Cancer Res., 52: 3961-3964, 1992.
8. Hein, D. W., Rustan, T. D., and Grant, D. M. Human liver polymorphic (NAT2) and monomorphic (NAT1) N-acetyltransferase isozymes catalyze metabolic activation of N-hydroxyarylamine and N-hydroxy-N-acetyl-arylamine proximate carcinogens. FASEB J., 6: A1274, 1992.
9. Kilbane, A. J., Silbart, L. K., Manis, M., Beitins, I. Z., and Weber, W. W. Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol. Ther., 47: 470-477, 1990.
10. Parkin, D. P., Vandenplas, S., Botha, F. J., Vandenplas, M. L., Seifart, H. I., vanHelden, P. D., van der Walt, B. J., Donald, P. R., and van Jaarsveld, P. P. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med., 155: 1717-1722, 1997.
11. Mitchell, R. S., and Bell, J. C. Clinical implications of isoniazid, PAS and streptomycin blood levels in pulmonary tuberculosis. Trans. Am. Clin. Chem. Assoc., 69: 98-105, 1957.
12. Ellard, G. A. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol. Ther., 19: 610-625, 1976.
13. Evans, D. A. P. Therapy. In: W. Kalow, H. W. Goedde, and D. P. Agarwa (eds.), Ethnic Differences in Reactions to Drugs and Xenobiotics, pp. 491-526. New York: Alan R. Liss, Inc., 1986.
14. Aynacioglu, A. S., Cascorbi, I., Mrozikiewicz, P. M., and Roots, I. Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics, 7: 327-331, 1997.
15. Slattery, M. L., Potter, J. D., Samowitz, W., Bigler, J., Caan, B., and Leppert, M. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Cancer Epidemiol. Biomark. Prev., 7: 1079-1084, 1998.
16. Chen, J., Stampfer, M. J., Hough, H. L., Garcia-Closas, M., Willett, W. C., Hennekens, C. H., Kelsey, K. T., and Hunter, D. J. A prospective study of N-acetyltransferase genotype, red meat intake and risk of colorectal cancer. Cancer Res., 58: 3307-3311, 1998.
17. Taylor, J. A., Umbach, D. M., Stephens, E., Castranio, T., Paulson, D., Robertson, C., Mohler, J. L., and Bell, D. A. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res., 58: 3603-3610, 1998.
18. Le Marchand, L., Sivaraman, L., Franke, A. A., Custer, L. J., Wilkens, L. R., Lau, A. F., and Cooney, R. V. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Cancer Epidemiol. Biomark. Prev., 5: 449-455, 1996.
19. Sinha, R., and Caporaso, N. Heterocyclic amines, cytochrome P450 1A2 and N-acetyltransferase: issues involved in incorporating putative genetic susceptibility markers into epidemiological studies. Ann. Epidemiol., 7: 350-356, 1997.
20. Blum, M., Grant, D. M., McBride, W., Heim, M., and Meyer, U. A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol., 9: 193-203, 1990.
21. Vincent-Viry, M., Pontes, Z. B., Gueguen, R., Galteau, M-M., and Siest, G. Segregation analyses of four urinary caffeine metabolic ratios implicated in the determination of human acetylation phenotypes. Genet. Epidemiol., 11: 115-129, 1994.
22. Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., and Kadlubar, F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2: 116-127, 1992.
23. Hein, D. W., Ferguson, R. J., Doll, M. A., Rustan, T. D., and Gray, K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol. Genet., 3: 729-734, 1994.
24. Graf, T., Broly, F., Hoffmann, F., Probst, M., Meyer, U. A., and Howald, H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur. J. Clin. Pharmacol., 43: 399-403, 1992.
25. Mrozikiewicz, P. M., Drakoulis, N., and Roots, I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin. Pharmacol. Ther., 50: 626-634, 1994.
26. Hickman, D., and Sim, E. N-Acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem. Pharmacol., 42: 1007-1014, 1991.
27. Rothman, N., Stewart, W. F., Caporaso, N. E., and Hayes, R. B. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol. Biomark. Prev., 2: 299-303, 1993.
28. Cascorbi, I., Drakoulis, N., Brockmöller, J., Maurer, A., Sperling, K., and Roots, I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet., 57: 581-592, 1995.
29. Ilett, K. F., Chiswell, G. M., Spargo, R. M., Platt, E., and Minchin, R. F. Acetylation phenotype and genotype in aboriginal leprosy patients from the northwest region of Western Australia. Pharmacogenetics, 3: 264-269, 1993.
30. Caporaso, N., Landi, M. T., and Vineis, P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1: 4-19, 1991.
31. Ilett, K. F., David, B. M., Detchon, P., Castleden, W. M., and Kwa, R. Acetylation phenotype in colorectal carcinoma. Cancer Res., 47: 1466-1469, 1987.
32. LeMarchand, L., and Kolonel, L. N. Cancer in Japanese migrants to Hawaii: interaction between genes and environment (in French). Rev. Epidemiol. Santé Publique, 40: 425-430, 1992.
33. Cascorbi, I., Brockmöller, J., Mrozikiewicz, P. M., Bauer, S., Loddenkemper, R., and Roots, I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res., 56: 3961-3966, 1996.
34. Ambrosone, C. B., Freudenheim, J. L., Graham, S., Marshall, J. R., Vena, J. E., Brasure, J. R., Michalek, A. M., Laughlin, R., Nemoto, T., Gillenwater, K. A., and Shields, P. G. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. J. Am. Med. Assoc., 276: 1494-1501, 1996.
35. Millikan, R. C., Pittman, G. S., Newman, B., Tse, C-K. J., Selmin, O., Rockhill, B., Savitz, D., Moorman, P. G., and Bell, D. A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 371-378, 1998.
36. Gertig, D. M., Hankinson, S. E., Hough, H., Spiegelman, D., Colditz, G. A., Willett, W. C., Kelsey, K. T., and Hunter, D. J. N-acetyl transferase 2 genotypes, meat intake and breast cancer risk. Int. J. Cancer, 80: 13-17, 1999.
37. Vineis, P., Caporaso, N., Tannenbaum, S. R., Skipper, P. L., Glogowski, J., Bartsch, H., Coda, M., Talaska, G., and Kadlubar, F. F. Acetylation phenotype, carcinogen-hemoglobin adducts and cigarette smoking. Cancer Res., 50: 3002-3004, 1990.
38. Okkels, H., Sigsgaard, T., Wolf, H., and Autrup, H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomark. Prev., 6: 225-231, 1997.
39. Silverman, B. W. Density Estimation for Statistics and Data Analysis, pp. 13-19. New York: Chapman and Hall, 1986.
40. Vatsis, K. P., Weber, W. W., Bell, D. A., Dupret, J. M., Evans, D. A., Grant, D. M., Hein, D. W., Lin H. J., Meyer, U. A., Relling, M. V., Sim, E., Suzuki, T., and Yamazoe, Y. Nomenclature for N-acetyltransferases. Pharmacogenetics, 5: 1-17, 1995.
41. Grant, D. M. Molecular genetics of the N-acetyltransferases. Pharmacogenetics, 3: 45-50, 1993.
42. Abe, M., Suzuki, T., and Deguchi, T. An improved method for genotyping of N-acetyltransferase polymorphism by polymerase chain reaction. Jpn. J. Hum. Genet., 38: 163-168, 1993.
43. Jackson, P. R., Tucker, G. T., and Woods, H. F. Testing for bimodality in frequency distribution of data suggesting polymorphisms of drug metabolism: histograms and probit plots. Br. J. Clin. Pharm., 28: 647-653, 1989.
44. Cohen, J. A coefficient of agreement for nominal scales. Ed. Psychol. Meas. 20: 37-46, 1960.
45. Lin, H. J., Han, C. Y., Lin, B. K., and Hardy, S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: application to metabolic epidemiology. Am. J. Hum. Genet., 52: 827-834, 1993.
46. Bell, D. A., Taylor, J. A., Butler, M. A., Stephens, E. A., Wiest, J., Brubaker, L. H., Kadlubar, F. F., and Lucier, G. W. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis (Lond.), 14: 1689-1692, 1993.
47. Cascorbi, I., Brockmöller, J., Bauer, S., Reum, T., and Roots, I. NAT2*12A (803A→G)codes for rapid arylamine N-acetylation in humans. Pharmacogenetics, 6: 257-259, 1996.